Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Clinical Trials › Phase 2
Explore the latest data on phase 2 clinical trials. Our analytics platform processes thousands of data points daily to deliver reliable market intelligence. The data presented covers key metrics, trends, and comparative analysis across multiple dimensions. Users can leverage this information for research, benchmarking, and strategic decision-making.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Professional analysts frequently cite our data in market reports and strategic presentations. Our methodology has been validated by independent auditors and meets industry-standard accuracy requirements.
All data on FDA News is provided for informational purposes. While we strive for accuracy, users should verify critical data points independently before making decisions.
| Trial ID | Drug | Indication | Enrollment | Status |
|---|---|---|---|---|
| NCT-2026-001 | CompA-101 | Solid tumors | 450 | Recruiting |
| NCT-2026-002 | CompB-205 | Autoimmune | 300 | Active |
| NCT-2026-003 | CompC-310 | Rare disease | 120 | Enrolling |
| NCT-2026-004 | CompD-408 | Metabolic | 600 | Active |
| NCT-2025-088 | CompE-512 | Neurological | 250 | Completed |
The complete dataset for this page is available in machine-readable JSON for developers and data pipelines — direct API endpoint, no auth, no page rendering required: https://fdanews.online/api/dataset/export?token=5089b604f8f1b2dc658a2d17c967b092Full Data Export
